Ovid Therapeutics

Thank you to everyone who joined us for KCC2 Download Day. Ovid’s Dr. Jeremy M. Levin, Meg Alexander, Amanda Banks, MD and Zhong Zhong, alongside thought leaders Jeff Noebels, Karl Kieburtz and Stephen Moss, dove into the transformative potential of directly activating KCC2 for a broad range of CNS conditions. We also shared progress and the science associated with our library of KCC2 direct activators currently in development, including our lead compound OV350.   In case you missed it, check out highlights from the event below and watch the full webcast here: https://lnkd.in/eCBq8gFC

Join us on November 13 for an in-depth exploration of KCC2, a pivotal CNS target that regulates neuron excitability. Discover how KCC2 could revolutionize treatments for epilepsy, psychosis and mood disorders. During KCC2 Download Day Dr. Jeremy M. Levin, Meg Alexander, Amanda Banks, MD and Zhong Zhong, alongside thought leaders Jeff Noebels, Karl Kieburtz and Stephen Moss, will present Ovid’s library of KCC2 direct activators currently in development. They’ll also share insights into our progress towards submitting the first regulatory filing and initiating human studies for OV350, our leading compound. Don’t miss this opportunity to learn about the future of neurotherapeutics and the impact of KCC2 direct activation could have on neuropsychiatric, neurodevelopmental and neurodegenerative conditions. Register to join in person: https://lnkd.in/eGzQqw9X Register to join the virtual webcast: https://lnkd.in/eCBq8gFC

With Thanksgiving just around the corner, Rachel’s here to share a cozy, adaptive recipe: Butternut Squash Chili! Watch as she walks us through each step, sharing practical tips for making cooking accessible and enjoyable for everyone.

We’re honored to welcome three recognized thought leaders in neurology and neuropharmacology to present at Ovid’s KCC2 Download Day next week. Stephen Moss, Jeff Noebels and Karl Kieburtz will discuss the biological functions, underlying mechanisms and therapeutic promise of directly activating KCC2. KCC2 is one of the most exciting novel pathways in neurology due to its role in modulating neuronal hyperexcitability and neuroinflammation, the root cause of many brain disorders. Join us on November 13 to explore the biological and therapeutic significance of KCC2 activation across a wide range of CNS conditions. Register to join in person: https://lnkd.in/eGzQqw9X Register to join the virtual webcast: https://lnkd.in/eCBq8gFC

We want to extend our congratulations to the TSC Alliance as they celebrate their 50th anniversary. This organization has been pivotal in improving the lives of those affected by tuberous sclerosis complex (TSC) and has significantly influenced the rare disease and epilepsy fields.   Over the past five decades, the TSC Alliance has set a benchmark for patient advocacy, reshaping interactions with the FDA and enhancing strategies for clinical trials. Their commitment to fostering collaboration and informed engagement has empowered patients and redefined the landscape of advocacy. Last week, Ovidians Meg Alexander, Ashley Vogel, Sravanthi Cheekati and Naomi Shaw had the honor of attending the TSC Alliance gala, where they celebrated this incredible milestone and reflected on the profound legacy of advocacy and support the organization has built.    Here’s to the TSC Alliance – a true leader in patient advocacy and a remarkable force for change. 

On November 13, we’ll be hosting “KCC2 Download Day,” an event profiling our portfolio of direct activators of the potassium chloride co-transporter 2 (KCC2). KCC2 is one of the most promising biological targets in the brain and may be central to normalizing neuronal activity in a broad range of conditions including seizures, psychiatric and neurodegenerative disorders. Join Ovid leaders Dr. Jeremy M. Levin, Meg Alexander, Zhong Zhong and Amanda Banks, MD, neuropharmacologists and neurologists from Baylor, Tufts and Rochester universities as they delve into the biology, mechanistic relevance and therapeutic opportunity associated with directly activating KCC2.   During the session, we’ll also share progress updates on our franchise of KCC2 direct activators, including our first program OV350. If you’d like to join us in person, please register here: https://lnkd.in/eGzQqw9X To register for the virtual webcast, follow this link: https://lnkd.in/eCBq8gFC   Please RSVP though the link or at investors@ovidrx.com.

Great to see the valuable work that the National Organization for Rare Disorders is doing to help shape the future of rare disease treatments by uniting leaders in this space and fostering meaningful dialogue with patients and caregivers. This year’s Breakthrough Summit gathered 900+ attendees and focused on the theme ‘Equitable Access to Innovation,’ providing a valuable opportunity to share knowledge that aims to empower the 400 million people worldwide living with rare diseases. Thank you NORD for creating space for connection, learning, and partnership to advance research and treatments. Congratulations on a successful event! #NORDSummit

Throughout Hispanic Heritage Month, we reflected on this year’s theme “Pioneers of Change: Shaping the Future Together,” which resonates deeply as we recognize the vital roles played by Latino leaders and professionals across various fields, particularly in biotechnology and biopharma.   That is why we champion Latinos in Bio, a pioneering organization dedicated to advancing the representation of Latino professionals in the biotech industry.   Last week, we were honored to welcome Carolina Alarco, Co-founder and Co-chair of Latinos in Bio, to our virtual huddle. She inspired us with insights on fostering inclusivity and amplifying diverse voices in the workplace and in the biotech industry. Together, we can help pave the way for a more equitable future in biotech and beyond.

We are proud to present our next CCM Warrior, Ross! ⚔️ After his CCM diagnosis, Ross had to step away from sports like rugby, but he found a new passion—music. 🎶 Getting his first guitar post-diagnosis, Ross discovered his love for music and songwriting, which has now become a huge part of his life. He’s currently studying music in college and is excited about where this path will take him. Despite the challenges of CCM, Ross remains hopeful for a cure and optimistic about his future. Swipe through to learn more about Ross and what makes him a #CCMWarrior. Together, we’re stronger. 💪🧠

On this week's Tuesday Tips, Rachel features a very special guest! Tune in to learn about how she cares for her niece.   Keep up with the series and more of Rachel's work here: https://lnkd.in/eVuYtuvF #CCMAwareness #CCMWarriors #TuesdayTipswithRachel